View ValuationCantourage Group 将来の成長Future 基準チェック /56Cantourage Group利益と収益がそれぞれ年間56.2%と27.9%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に12.6% 26.4%なると予測されています。主要情報56.2%収益成長率26.42%EPS成長率Pharmaceuticals 収益成長23.7%収益成長率27.9%将来の株主資本利益率12.60%アナリストカバレッジLow最終更新日12 May 2026今後の成長に関する最新情報Price Target Changed • Mar 09Price target increased by 9.1% to €9.00Up from €8.25, the current price target is an average from 2 analysts. New target price is 74% above last closing price of €5.18. Stock is up 12% over the past year.Major Estimate Revision • Sep 08Consensus revenue estimates fall by 13%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €100.3m to €87.1m. EPS estimate fell from €0.34 to €0.16 per share. Net income forecast to grow 2,359% next year vs 49% growth forecast for Pharmaceuticals industry in Germany. Consensus price target down from €13.00 to €10.25. Share price fell 5.9% to €3.70 over the past week.Price Target Changed • Sep 06Price target decreased by 18% to €10.25Down from €12.50, the current price target is an average from 2 analysts. New target price is 177% above last closing price of €3.70. Stock is down 28% over the past year.Major Estimate Revision • Jan 29Consensus estimates of losses per share improve by 33%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €50.3m to €51.4m. EPS estimate increased from -€0.03 per share to -€0.02 per share. Pharmaceuticals industry in Germany expected to see average net income growth of 31% next year. Consensus price target up from €12.00 to €12.25. Share price rose 4.9% to €5.10 over the past week.Major Estimate Revision • Jan 21Consensus estimates of losses per share improve by 75%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €48.8m to €50.3m. EPS estimate increased from -€0.02 per share to -€0.005 per share. Pharmaceuticals industry in Germany expected to see average net income growth of 31% next year. Consensus price target up from €11.75 to €12.00. Share price was steady at €4.86 over the past week.Price Target Changed • Dec 05Price target increased by 7.5% to €10.75Up from €10.00, the current price target is an average from 2 analysts. New target price is 141% above last closing price of €4.46. Stock is down 39% over the past year.すべての更新を表示Recent updatesお知らせ • May 14Cantourage Group SE, Annual General Meeting, Jun 24, 2026Cantourage Group SE, Annual General Meeting, Jun 24, 2026, at 11:00 W. Europe Standard Time.お知らせ • Mar 27Cantourage Group SE to Report Fiscal Year 2025 Results on May 15, 2026Cantourage Group SE announced that they will report fiscal year 2025 results at 12:00 PM, Central European Standard Time on May 15, 2026Price Target Changed • Mar 09Price target increased by 9.1% to €9.00Up from €8.25, the current price target is an average from 2 analysts. New target price is 74% above last closing price of €5.18. Stock is up 12% over the past year.分析記事 • Dec 24An Intrinsic Calculation For Cantourage Group SE (ETR:HIGH) Suggests It's 32% UndervaluedKey Insights Using the 2 Stage Free Cash Flow to Equity, Cantourage Group fair value estimate is €4.98 Cantourage Group...New Risk • Sep 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (€2.2m revenue, or US$2.6m). Market cap is less than US$100m (€45.6m market cap, or US$53.5m).分析記事 • Sep 09Cantourage Group SE's (ETR:HIGH) Intrinsic Value Is Potentially 56% Above Its Share PriceKey Insights The projected fair value for Cantourage Group is €5.51 based on 2 Stage Free Cash Flow to Equity...Major Estimate Revision • Sep 08Consensus revenue estimates fall by 13%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €100.3m to €87.1m. EPS estimate fell from €0.34 to €0.16 per share. Net income forecast to grow 2,359% next year vs 49% growth forecast for Pharmaceuticals industry in Germany. Consensus price target down from €13.00 to €10.25. Share price fell 5.9% to €3.70 over the past week.Price Target Changed • Sep 06Price target decreased by 18% to €10.25Down from €12.50, the current price target is an average from 2 analysts. New target price is 177% above last closing price of €3.70. Stock is down 28% over the past year.お知らせ • May 19Cantourage Group SE, Annual General Meeting, Jun 25, 2025Cantourage Group SE, Annual General Meeting, Jun 25, 2025, at 13:00 W. Europe Standard Time.New Risk • Apr 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Revenue is less than US$5m (€2.0m revenue, or US$2.1m). Market cap is less than US$100m (€55.5m market cap, or US$60.8m).お知らせ • Mar 09Cantourage Group SE to Report First Half, 2025 Results on Oct 31, 2025Cantourage Group SE announced that they will report first half, 2025 results on Oct 31, 2025Major Estimate Revision • Jan 29Consensus estimates of losses per share improve by 33%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €50.3m to €51.4m. EPS estimate increased from -€0.03 per share to -€0.02 per share. Pharmaceuticals industry in Germany expected to see average net income growth of 31% next year. Consensus price target up from €12.00 to €12.25. Share price rose 4.9% to €5.10 over the past week.Major Estimate Revision • Jan 21Consensus estimates of losses per share improve by 75%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €48.8m to €50.3m. EPS estimate increased from -€0.02 per share to -€0.005 per share. Pharmaceuticals industry in Germany expected to see average net income growth of 31% next year. Consensus price target up from €11.75 to €12.00. Share price was steady at €4.86 over the past week.Price Target Changed • Dec 05Price target increased by 7.5% to €10.75Up from €10.00, the current price target is an average from 2 analysts. New target price is 141% above last closing price of €4.46. Stock is down 39% over the past year.Price Target Changed • Jul 18Price target increased by 10% to €11.00Up from €10.00, the current price target is provided by 1 analyst. New target price is 59% above last closing price of €6.90. Stock is down 36% over the past year.お知らせ • May 17Cantourage Group SE, Annual General Meeting, Jun 26, 2024Cantourage Group SE, Annual General Meeting, Jun 26, 2024, at 13:00 W. Europe Standard Time.New Risk • Feb 12New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Shareholders have been diluted in the past year (5.0% increase in shares outstanding).New Risk • Feb 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change).分析記事 • Jan 05Calculating The Intrinsic Value Of Cantourage Group SE (ETR:HIGH)Key Insights Using the 2 Stage Free Cash Flow to Equity, Cantourage Group fair value estimate is €6.86 Cantourage...New Risk • Dec 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €92.4m (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (€92.4m market cap, or US$99.9m).New Risk • Aug 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).お知らせ • Jul 22Cantourage Group SE Provides Earnings Guidance for the Fiscal Year 2023Cantourage Group SE provided earnings guidance for the fiscal year 2023. For the year, the company expects sales growth to be in the higher double-digit percentage range compared to the previous year.New Risk • Jun 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Share price has been volatile over the past 3 months (7.2% average weekly change).業績と収益の成長予測XTRA:HIGH - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202813277N/A212/31/202711357N/A312/31/202610248N/A312/31/202540N/AN/AN/A9/30/202530N/AN/AN/A6/30/202520N/AN/AN/A3/31/202520N/AN/AN/A12/31/202420N/AN/AN/A9/30/202420N/AN/AN/A6/30/202420N/AN/AN/A3/31/202420N/AN/AN/A12/31/202320N/AN/AN/A9/30/202310N/AN/AN/A6/30/202310N/AN/AN/A12/31/202210N/AN/AN/A12/31/20215-1N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: HIGHの予測収益成長率 (年間56.2% ) は 貯蓄率 ( 1.9% ) を上回っています。収益対市場: HIGHの収益 ( 56.2% ) はGerman市場 ( 17% ) よりも速いペースで成長すると予測されています。高成長収益: HIGHの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: HIGHの収益 ( 27.9% ) German市場 ( 6.8% ) よりも速いペースで成長すると予測されています。高い収益成長: HIGHの収益 ( 27.9% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: HIGHの 自己資本利益率 は、3年後には低くなると予測されています ( 12.6 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 06:10終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cantourage Group SE 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Ellis AcklinFirst Berlin Equity Research GmbHTim KruseMontega AGIngo SchmidtMontega AG1 その他のアナリストを表示
Price Target Changed • Mar 09Price target increased by 9.1% to €9.00Up from €8.25, the current price target is an average from 2 analysts. New target price is 74% above last closing price of €5.18. Stock is up 12% over the past year.
Major Estimate Revision • Sep 08Consensus revenue estimates fall by 13%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €100.3m to €87.1m. EPS estimate fell from €0.34 to €0.16 per share. Net income forecast to grow 2,359% next year vs 49% growth forecast for Pharmaceuticals industry in Germany. Consensus price target down from €13.00 to €10.25. Share price fell 5.9% to €3.70 over the past week.
Price Target Changed • Sep 06Price target decreased by 18% to €10.25Down from €12.50, the current price target is an average from 2 analysts. New target price is 177% above last closing price of €3.70. Stock is down 28% over the past year.
Major Estimate Revision • Jan 29Consensus estimates of losses per share improve by 33%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €50.3m to €51.4m. EPS estimate increased from -€0.03 per share to -€0.02 per share. Pharmaceuticals industry in Germany expected to see average net income growth of 31% next year. Consensus price target up from €12.00 to €12.25. Share price rose 4.9% to €5.10 over the past week.
Major Estimate Revision • Jan 21Consensus estimates of losses per share improve by 75%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €48.8m to €50.3m. EPS estimate increased from -€0.02 per share to -€0.005 per share. Pharmaceuticals industry in Germany expected to see average net income growth of 31% next year. Consensus price target up from €11.75 to €12.00. Share price was steady at €4.86 over the past week.
Price Target Changed • Dec 05Price target increased by 7.5% to €10.75Up from €10.00, the current price target is an average from 2 analysts. New target price is 141% above last closing price of €4.46. Stock is down 39% over the past year.
お知らせ • May 14Cantourage Group SE, Annual General Meeting, Jun 24, 2026Cantourage Group SE, Annual General Meeting, Jun 24, 2026, at 11:00 W. Europe Standard Time.
お知らせ • Mar 27Cantourage Group SE to Report Fiscal Year 2025 Results on May 15, 2026Cantourage Group SE announced that they will report fiscal year 2025 results at 12:00 PM, Central European Standard Time on May 15, 2026
Price Target Changed • Mar 09Price target increased by 9.1% to €9.00Up from €8.25, the current price target is an average from 2 analysts. New target price is 74% above last closing price of €5.18. Stock is up 12% over the past year.
分析記事 • Dec 24An Intrinsic Calculation For Cantourage Group SE (ETR:HIGH) Suggests It's 32% UndervaluedKey Insights Using the 2 Stage Free Cash Flow to Equity, Cantourage Group fair value estimate is €4.98 Cantourage Group...
New Risk • Sep 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (€2.2m revenue, or US$2.6m). Market cap is less than US$100m (€45.6m market cap, or US$53.5m).
分析記事 • Sep 09Cantourage Group SE's (ETR:HIGH) Intrinsic Value Is Potentially 56% Above Its Share PriceKey Insights The projected fair value for Cantourage Group is €5.51 based on 2 Stage Free Cash Flow to Equity...
Major Estimate Revision • Sep 08Consensus revenue estimates fall by 13%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €100.3m to €87.1m. EPS estimate fell from €0.34 to €0.16 per share. Net income forecast to grow 2,359% next year vs 49% growth forecast for Pharmaceuticals industry in Germany. Consensus price target down from €13.00 to €10.25. Share price fell 5.9% to €3.70 over the past week.
Price Target Changed • Sep 06Price target decreased by 18% to €10.25Down from €12.50, the current price target is an average from 2 analysts. New target price is 177% above last closing price of €3.70. Stock is down 28% over the past year.
お知らせ • May 19Cantourage Group SE, Annual General Meeting, Jun 25, 2025Cantourage Group SE, Annual General Meeting, Jun 25, 2025, at 13:00 W. Europe Standard Time.
New Risk • Apr 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Revenue is less than US$5m (€2.0m revenue, or US$2.1m). Market cap is less than US$100m (€55.5m market cap, or US$60.8m).
お知らせ • Mar 09Cantourage Group SE to Report First Half, 2025 Results on Oct 31, 2025Cantourage Group SE announced that they will report first half, 2025 results on Oct 31, 2025
Major Estimate Revision • Jan 29Consensus estimates of losses per share improve by 33%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €50.3m to €51.4m. EPS estimate increased from -€0.03 per share to -€0.02 per share. Pharmaceuticals industry in Germany expected to see average net income growth of 31% next year. Consensus price target up from €12.00 to €12.25. Share price rose 4.9% to €5.10 over the past week.
Major Estimate Revision • Jan 21Consensus estimates of losses per share improve by 75%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €48.8m to €50.3m. EPS estimate increased from -€0.02 per share to -€0.005 per share. Pharmaceuticals industry in Germany expected to see average net income growth of 31% next year. Consensus price target up from €11.75 to €12.00. Share price was steady at €4.86 over the past week.
Price Target Changed • Dec 05Price target increased by 7.5% to €10.75Up from €10.00, the current price target is an average from 2 analysts. New target price is 141% above last closing price of €4.46. Stock is down 39% over the past year.
Price Target Changed • Jul 18Price target increased by 10% to €11.00Up from €10.00, the current price target is provided by 1 analyst. New target price is 59% above last closing price of €6.90. Stock is down 36% over the past year.
お知らせ • May 17Cantourage Group SE, Annual General Meeting, Jun 26, 2024Cantourage Group SE, Annual General Meeting, Jun 26, 2024, at 13:00 W. Europe Standard Time.
New Risk • Feb 12New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Shareholders have been diluted in the past year (5.0% increase in shares outstanding).
New Risk • Feb 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change).
分析記事 • Jan 05Calculating The Intrinsic Value Of Cantourage Group SE (ETR:HIGH)Key Insights Using the 2 Stage Free Cash Flow to Equity, Cantourage Group fair value estimate is €6.86 Cantourage...
New Risk • Dec 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €92.4m (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (€92.4m market cap, or US$99.9m).
New Risk • Aug 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).
お知らせ • Jul 22Cantourage Group SE Provides Earnings Guidance for the Fiscal Year 2023Cantourage Group SE provided earnings guidance for the fiscal year 2023. For the year, the company expects sales growth to be in the higher double-digit percentage range compared to the previous year.
New Risk • Jun 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Share price has been volatile over the past 3 months (7.2% average weekly change).